Nicholas Marston

MD | MPH | Preventive Cardiologist @BrighamWomens & @HarvardMed | Clinical Trialist & Investigator @TIMIStudyGroup & @Broadinstitute | Lipids, Genetics, Trials

[Circulation @CircAHA]

#SimPub #ACC26 In CCTA substudy of Essence-TIMI 73b (RCT of olezarsen vs. placebo in patients with hypertriglyceridemia), no difference in non calcified, coronary plaque volu... @marstonMD @maciejbanach @AndreZimerman @michael_t_lu @BrianBergmark @BudoffMd https://t.co/huWruTtamz

[Nicholas Marston @marstonMD]

@kaulcsmc Pts w/ a single 50-70% stenosis of a coronary or carotid artery did not meet criteria for "qualifying" athero, so these patients are in high-risk DM group in NEJM paper

But in this analysis of pts without known "significant" athero, we did not want these 50-70% stenoses included

[Nicholas Marston @marstonMD]

A great team effort as always, and I especially enjoyed the collaboration with friend, colleague, and EC expert @Dr_RajatGupta on this one.
@KamanuFred @TIMIStudyGroup

[Nicholas Marston @marstonMD]

Now out in @NatureMedicine, we developed an Endothelial Cell PRS for CAD that:

1) Quantifies a currently immeasurable axis of CAD risk

2) Identifies individuals who are LDL-sensitive

3) Establishes which Pts will have greatest CV benefit from early & aggressive lipid lowering

[Nicholas Marston @marstonMD]

Link to paper here: https://t.co/bXBrO4ksta

[Nicholas Marston @marstonMD]

A big thanks to @dan_soffer for leading this effort, it was fun to collaborate with such a great team! @CBallantyneMD @jpenamd @SethShayMartin @ThanassoulisMD @carolkirkpat3 @giorgio_melloni @nationallipid @LipidJournal @TIMIStudyGroup

[Nicholas Marston @marstonMD]

Honored to be a part of the @NationalLipid Association's Expert Clinical Consensus on the Role of ApoB in the Clinical Management of Cardiovascular Risk in Adults.

When should we be checking apoB?

How low should we go?

See link and thread below...

https://t.co/lYq6RA81J8

[Nicholas Marston @marstonMD]

To summarize, apoB is a precise, accurate, and well-validated measure that provides information not available on standard lipid panels

Incorporation of apoB into clinical practice identifies patients at higher CV risk than appreciated who may warrant intensification of therapy

[Journal of Clinical Lipidology @LipidJournal]

Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association - Journal of Clinical Lipidology @nationallipid
https://t.co/bXAOK0Xtej